Taysha Gene Therapies Inc (TSHA)
3.09
-0.05
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
3.08
-0.01
(-0.32%)
After-Hours: 20:00
Taysha Gene Therapies Revenue (Quarterly): 3.411M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.411M |
| December 31, 2023 | 3.604M |
| September 30, 2023 | 4.746M |
| Date | Value |
|---|---|
| June 30, 2023 | 2.395M |
| March 31, 2023 | 4.706M |
| December 31, 2022 | 2.502M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.395M
Minimum
Jun 2023
4.746M
Maximum
Sep 2023
3.561M
Average
3.508M
Median
Revenue (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 12.05M |
| Lifecore Biomedical Inc | 31.55M |
| Relmada Therapeutics Inc | -- |
| ACADIA Pharmaceuticals Inc | 205.83M |
| Cyclacel Pharmaceuticals Inc | 0.031M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -24.06M |
| Total Expenses (Quarterly) | 27.74M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 494.42M |
| Profit Margin (Quarterly) | -705.4% |
| Earnings Yield | -37.37% |
| Normalized Earnings Yield | -20.04 |